EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy

Priscila da Silva, Javier Mora, Xin You, Svenja Wiechmann, Mateusz Putyrski, Javier Garcia-Pardo, Aimo Kannt, Andreas Ernst, Bernhard Bruene, Andreas Weigert iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Priscila da Silva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Institute of Biochemistry I, Goethe-University Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Antibodies, Neutralizing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Hessen State Ministry for Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The interleukin (IL)-1-family receptor antagonist IL-38 has emerged as a negative regulator of auto-inflammation. Given the intricate interplay between antitumor immunity and auto-inflammation, we hypothesized that blocking IL-38 may enhance tumor immune control.

Methods

Our hypothesis was tested in the transgenic polyoma virus middle T oncoprotein mammary carcinoma model that is suitable for identifying strong immunomodulators. To investigate the effect of acute IL-38 blockade, we used a neutralizing antibody, alone or in combination with chemotherapy. Immune cell composition and location in tumors were determined by flow cytometry and immunohistochemistry, respectively. The role of γδ T cells was studied using an antibody blocking γδ T-cell receptor signaling. Whole transcriptome RNA sequencing and RNA expression analysis were employed to determine mechanisms downstream of IL-38 neutralization. Additionally, in vitro assays with γδ T cells, CD8+ T cells and cDC1, followed by in vivo CD8+ T cell depletion, were performed to study the underlying mechanistic pathways.

Results

Both, genetic ablation of IL-38 and neutralization with the antibody, reduced tumorigenesis, and IL-38 blockade improved chemotherapy efficacy. This was accompanied by an augmented lymphocyte infiltrate dominated by γδ T cells and CD8+ T cells, and signaling through the γδ-T-cell receptor was required for CD8+ T cell infiltration. Rather than directly interacting with CD8+ T cells, γδ T cells recruited conventional dendritic cells (cDC1) into tumors via the chemokine Xcl1. cDC1 in turn activated CD8+ T cells via the Notch pathway. Moreover, IL-38 negatively correlated with cDC1, XCL1-producing γδ T cells, T-cell infiltrates and survival in patients with mammary carcinoma.

Conclusions

These data suggest that interfering with IL-38 improves antitumor immunity even in immunologically cold tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAnimalsFemaleHumansMiceCD8-Positive T-LymphocytesCell Line, TumorInterleukin-1Receptors, Antigen, T-Cell, gamma-delta

Stichwörter der Autor:innen

AntibodyBreast CancerChemotherapyT cell

Substanzen

Antibodies, NeutralizingInterleukin-1Receptors, Antigen, T-Cell, gamma-deltaIL1F10 protein, humanIl1f10 protein, mouse

Autor:innen und Institutionen

  • Faculty of Medicine, Institute of Biochemistry I, Goethe-University Frankfurt, Frankfurt, Germany.
  • Faculty of Microbiology, University of Costa Rica, San José, Costa Rica.
  • Centro de Investigación en Cirugía y Cancer (CICICA), University of Costa Rica, 2060 San José, Costa Rica.
  • Centro de Investigación en Enfermedades Tropicales (CIET), University of Costa Rica, San José, Costa Rica.
  • Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Frankfurt, Germany.
  • Institut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Andreas Weigert

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe
  • Hessen State Ministry for Higher Education

Zitieren

APA

da Silva, P., Mora, J., You, X., Wiechmann, S., Putyrski, M., Garcia-Pardo, J., Kannt, A., Ernst, A., Bruene, B., & Weigert, A. (2024). Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008641

Vancouver

da Silva P, Mora J, You X, Wiechmann S, Putyrski M, Garcia-Pardo J, et al. Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008641

BibTeX
@article{daSilva2024,
  author = {da Silva, Priscila and Mora, Javier and You, Xin and Wiechmann, Svenja and Putyrski, Mateusz and Garcia-Pardo, Javier and Kannt, Aimo and Ernst, Andreas and Bruene, Bernhard and Weigert, Andreas},
  title = {Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008641}
}
Kostenlos starten →